<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960293</url>
  </required_header>
  <id_info>
    <org_study_id>4-2021-0467</org_study_id>
    <nct_id>NCT04960293</nct_id>
  </id_info>
  <brief_title>Spherical Gelfoam Versus Tri-acryl Microsphere for Uterine Artery Embolization for Symptomatic Fibroids</brief_title>
  <official_title>&quot;Comparison of Pain After Uterine Artery Embolization Using Spherical Gelfoam or Tris-acryl Gelatin Microsphere in Patients With Symptomatic Fibroids: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare pain after uterine artery embolization using&#xD;
      spherical gelfoam or tris-acryl gelatin microsphere in patients with symptomatic fibroids&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine artery embolization(UAE) is a minimally invasive treatment alternative to&#xD;
      hysterectomy and myomectomy in symptomatic fibroids. However, post-procedural pain after UAE&#xD;
      remains a major problem. The spherical gelfoam and tri-acryl gelatin microsphere are two&#xD;
      embolic materials used for UAE. Therefore, the aim of study is to compare pain intensity and&#xD;
      inflammation after uterine artery embolization using the two embolic agents with symptomatic&#xD;
      fibroids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score (VAS score)</measure>
    <time_frame>up to 24 hours after embolization</time_frame>
    <description>Maximum pain score measured during 24 hours after embolization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (mg/L)</measure>
    <time_frame>the day before and 24 hours after embolization</time_frame>
    <description>inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis rate after embolization</measure>
    <time_frame>1 day and 3 months after embolization</time_frame>
    <description>technical success indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity questionnaire</measure>
    <time_frame>before and 3 months after embolization</time_frame>
    <description>clinical success indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count (/µL)</measure>
    <time_frame>the day before and 24 hours after embolization</time_frame>
    <description>inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil percentage (%)</measure>
    <time_frame>the day before and 24 hours after embolization</time_frame>
    <description>inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative fentanyl dose (µg)</measure>
    <time_frame>within 24 hours after embolization</time_frame>
    <description>Total amount of IV fentanyl administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue analgesics (%)</measure>
    <time_frame>within 24 hours after embolization</time_frame>
    <description>Necessity of additional rescue analgesics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte percentage (%)</measure>
    <time_frame>the day before and 24 hours after embolization</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Symptomatic Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Spherical gelfoam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive uterine artery embolization for symptomatic fibroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microsphere</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who receive uterine artery embolization for symptomatic fibroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>uterine artery embolization using spherical gelfoam</intervention_name>
    <description>Uterine artery embolization is performed using spherical gelfoam. All other processes are same.</description>
    <arm_group_label>Spherical gelfoam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>uterine artery embolization using tri-acryl gelatin microsphere</intervention_name>
    <description>Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.</description>
    <arm_group_label>Microsphere</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Women with symptomatic fibroids (age: 20 - 60 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bradycardia (&lt;45 bpm)&#xD;
&#xD;
          2. Conduction abnormalities&#xD;
&#xD;
          3. Liver failure&#xD;
&#xD;
          4. renal failure&#xD;
&#xD;
          5. Uncontrolled hypertension&#xD;
&#xD;
          6. High grade obesity (BMI ≥ 30 kg/m2)&#xD;
&#xD;
          7. Drug allergy&#xD;
&#xD;
          8. Illiteracy&#xD;
&#xD;
          9. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Man-Deuk Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiology, Severance hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Man-Deuk Kim</last_name>
    <phone>82-10-8625-2197</phone>
    <email>mdkim@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Man-Deuk Kim</last_name>
      <phone>82-10-8625-2197</phone>
      <email>mdkim@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibroid</keyword>
  <keyword>Embolization</keyword>
  <keyword>Pain</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

